8-K: 180 Life Sciences Settles Dispute with Former Executive, Issues Shares and Secures Voting Agreement

180 Life Sciences Corp. resolves legal actions with Dr. Marlene Krauss, former executive of KBL Merger Corp. IV, by issuing shares, making a cash payment, and securing a voting agreement.

Summary

• 180 Life Sciences Corp. entered into a Mutual Settlement and General Release Agreement with Dr. Marlene Krauss and KBL IV Sponsor, LLC on February 21, 2025.
• The company will pay Dr. Krauss $50,000 within twenty days of the agreement date.
• 180 Life Sciences will issue 200,000 shares of restricted common stock to Dr. Krauss within three business days.
• Dr. Krauss will have piggyback registration rights for these shares for six months.
• Dr. Krauss entered into a Voting Agreement, agreeing to vote the Settlement Shares as recommended by the Board of Directors until August 21, 2025.
• Dr. Krauss granted Blair Jordan, the company's CEO, an irrevocable voting proxy to enforce the Voting Agreement.
• The Settlement Agreement requires Dr. Krauss to dismiss her court actions within ten days after receiving the cash payment.
• All parties will dismiss their claims against each other with prejudice.
• The Settlement Shares were issued without registration under the Securities Act of 1933, relying on exemptions.

Sentiment

Score: 7

Explanation: The settlement is a positive step for the company as it resolves outstanding legal issues. The voting agreement provides some stability. However, the issuance of shares dilutes existing shareholders.

Positives

• The settlement resolves outstanding legal disputes with Dr. Krauss and KBL Sponsor.
• The Voting Agreement provides the company with voting support from Dr. Krauss for key decisions until August 21, 2025.
• The dismissal of all claims with prejudice provides closure and reduces future legal risks.

Future Outlook

The company aims to finalize the settlement by making the cash payment, issuing shares, and obtaining the dismissal of all claims.

Industry Context

Settling disputes with former executives is a common occurrence in corporate governance, allowing companies to move forward without the distraction and expense of ongoing litigation. Securing voting agreements can provide stability and support for company initiatives.

Legal Proceedings

• The document details the settlement of legal actions between 180 Life Sciences, Dr. Marlene Krauss, and KBL IV Sponsor, LLC.
• The Advancement Action and the Claims Action in the Delaware Court will be dismissed with prejudice.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of 200,000 shares to Dr. Krauss.
• The settlement resolves uncertainty and potential costs associated with ongoing litigation, which benefits stakeholders.
• The voting agreement could influence future corporate decisions.

Next Steps

• 180 Life Sciences will make a $50,000 cash payment to Dr. Krauss within twenty days.
• The company will issue 200,000 shares of restricted common stock to Dr. Krauss within three business days.
• Dr. Krauss will file a dismissal of her court actions within ten days after receiving the cash payment.
• All parties will dismiss their claims against each other with prejudice.

Key Dates